Abstract Library

#2883 Comparison of Somatostatin Analogues in Metastatic Gastroenteropancreatic Neuroendocrine Tumors from a Bayesian Perspective: The GETNE-TRASGU Study

Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Lamarca A, Barriuso J, Castaño A,

Keywords: Bayesian model, octreotide, lanreotide, progression-free survival, efficacy,

#2715 The Role of Serum Concentration Ratio of Neuron-Specific Enolase in the Evaluation of Therapeutic Effect of Neuroendocrine Tumor

Introduction: There has been no good serum biomarker for the evaluation of the therapeutic effect of Neuroendocrine tumors（NET）

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Jingbao K,

Keywords: Neuroendocrine tumor, NSE Ratio, Therapeutic effect, Progression-free survival,

#2280 The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents

Introduction: Peptide radioreceptor therapy (PRRT) is a promising therapy option for SSTR2-positive pancreatic neuroendocrine neoplasms (NEN). However, therapeutic effects are often not satisfying concerning sensitivity to PRRT. We hypothesize that the slow proliferation of NENs provides sufficient time for the repair of beta-particle induced-DNA damage. The ubiquitin-proteasome-system is involved in DNA damage repair and affected by the proteasome inhibitor bortezomib (Velcade®). The inhibition of DNA damage repair during PRRT may be an option to improve therapy response in NEN. We have recently demonstrated the damage repair inhibitory and pro-apoptotic effect of bortezomib in NEN in vitro (Briest et al., in revision).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Briest F

Authors: Briest F, Grötzinger C, Exner S, Sedding D, Baum R,

Keywords: peptide radioreceptor therapy, Lu-177-DOTATOC, PRRT, bortezomib, in vivo model, SPECT/CT Imaging, chicken CAM model, Sensitizer, DNA damage repair,

#2136 Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors

Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tan H

Authors: Wang X, Li Y, Shi Y, Chen Y, Qiu X,

Keywords: thymic neuroendocrine tumors, capecitabine, temozolomide, progress-free survival, adverse effect,

#1721 Optimisation of the Size Variation Threshold for CT Evaluation of Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors Treated with Octreotide LAR

Introduction: In advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), somatostatin analogs treatment rarely achieve a reduction of -30% in the sum of longest diameters (SLD) of target lesions required by Response Evaluation Criteria in Solid Tumors (RECIST) for an ‘objective response’. The implication of Stable Disease (SD) as an additional indicator of therapeutic effect is often uncertain.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Luo Y

Authors: Luo Y, Chen J,

Keywords: GEP-NETs, Octreotide LAR, Progression-free Survival,